Objectives: This study aims to investigate how human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) affect the production of immunoglobulin M (IgM)-rheumatoid factor (RF).
Patients And Methods: The study included 405 voluntary participants (139 males, 266 females; mean age 39.4±17.9 years; range 3 to 88 years) randomly recruited by a consecutive sampling technique in the main health facilities of the Center, East, Far North, Littoral and West regions of Cameroon. We excluded persons under treatment or hospitalized for any form of primary autoimmune disease. Blood samples were collected and used for serological analyses. We sought for the HIV antibodies (Ab); the core antibody (HBcAb), the surface antigen (HBsAg), and the replicative antigen (HBeAg) of the HBV; HCVAb of HCV and the IgM-RF.
Results: The prevalence of HIVAb was 7.61%, 38.7% for HBcAb, 5.43% for HBsAg, 1.26% for HBeAg and 6.41% for IgM-RF in the study population. The Far North region had the highest prevalence of IgM-RF (9.8%) and the Littoral region had the lowest prevalence (3.2%). The prevalence of RF was 6.7% and 5.7% for females and males, respectively (sex ratio of 2.25). The IgM-RF prevalence was 9.7%, 8.9%, 9.1%, and 27.8% in participants with positive serological results for HIVAb, HBcAb, HBsAg, and HCV, respectively.
Conclusion: Infection by HIV and HBV showed to poorly stimulated IgM-RF production. However, IgM-RF was highly produced in HCV infected participants. Increased IgM-RF production may contribute to cytotoxicity in tissues or organs of HCV-infected patients, leading to the onset of autoimmune diseases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409169 | PMC |
http://dx.doi.org/10.5606/ArchRheumatol.2018.6076 | DOI Listing |
Front Med (Lausanne)
December 2024
Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Objective: To investigate the probability of hepatocellular carcinoma (HCC) in a large number of gray-zone (GZ) patients with chronic hepatitis B (CHB) in clinical practice.
Methods: The patients with CHB who were diagnosed and treated in our hospital from January 2013 to January 2023 were analyzed retrospectively.
Results: According to the different levels of HBeAg, ALT and HBV DNA, GZ patients were divided into four categories: (1) Gray zone A (GZ-A): HBeAg positive, normal ALT level, HBV DNA ≤ 10 IU/ml; (2) Gray zone B (GZ-B): HBeAg positive, ALT>ULN, HBV DNA ≤ 2 × 10 IU/ml; (3) Gray zone C (GZ-C): HBeAg negative, normal ALT level, HBV DNA ≥ 2 × 10 IU/ml; and (4) Gray zone D (GZ-D): HBeAg negative, ALT > ULN, serum HBV DNA ≤ 2 × 10 IU/ml.
Cureus
December 2024
General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to Be University), Pune, IND.
Liver Int
February 2025
Italian Liver Cancer (ITA.LI.CA) Association, Bologna, Italy.
Background And Aims: Presence of active hepatitis C virus (HCV) infection may influence the outcome of patients treated for hepatocellular carcinoma (HCC), although this issue has never been adequately assessed in a large series of patients. The aim of this study was to evaluate whether the presence of active HCV affects the survival of patients treated for HCC.
Methods: This study assessed the outcome of 3123 anti-HCV-positive patients with HCC, subdivided according to the presence of active HCV infection or previous sustained virological response (SVR).
Arq Gastroenterol
December 2024
Universidade Federal de São Paulo, São Paulo, SP, Brasil.
Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).
View Article and Find Full Text PDFArq Gastroenterol
December 2024
Department of Internal Medicine, Faculty of Medicine, Benha University, Benha, Egypt.
Objective: To investigate the ability of the estimated plasma gene-expression levels of microRNA (miR)-21 and 126 to define patients suspected to have hepatocellular carcinoma (HCC) among patients with complicated hepatitis-C virus (HCV) infection.
Methods: Patients with uncomplicated (U-HCV) or complicated HCV underwent clinical and ultrasonographic (US) evaluations and assessment for the computerized hepatorenal index, hepatic steatosis index and fibrosis indices. Blood samples were obtained for estimation of serum levels of alpha-fetoprotein (AFP) and tumor necrosis factor-α (TNF-α), and plasma expression levels of miR-21 and miR-126 using the quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!